ArticleFuture oncology (London, England)2025
Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection.
Mei Dai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.